Clearside Biomedical, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CLSD Nasdaq 2830 clearsidebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearside Biomedical, Inc.

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know - May 29th, 2025 10:00 am
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - May 21st, 2025 5:05 am
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates - May 14th, 2025 3:35 pm
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - May 14th, 2025 2:05 pm
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - May 9th, 2025 5:05 am
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 - May 8th, 2025 5:05 am
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know - May 1st, 2025 8:01 am
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference - May 1st, 2025 5:05 am
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Apr 1st, 2025 7:00 pm
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - Apr 1st, 2025 5:05 am
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Mar 29th, 2025 6:38 am
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Mar 27th, 2025 3:20 pm
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 27th, 2025 2:05 pm
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - Mar 24th, 2025 5:05 am
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit - Mar 20th, 2025 5:05 am
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 - Mar 12th, 2025 5:05 am
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD - Mar 6th, 2025 5:05 am
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains? - Feb 24th, 2025 8:25 am
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema - Feb 20th, 2025 5:05 am
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting - Feb 10th, 2025 5:05 am